ArticleInternational journal of clinical and experimental pathology2014
Ki-67/MIB-1 immunostaining in a cohort of human gliomas.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Guiding the first biopsy in glioma patients using estimated Ki-67 maps derived from MRI: conventional versus advanced imaging.Neuro-oncology · 2019Trial
- From tumor reduction to behavioral improvement and cytokine balance: Therapeutic role of petroleum ether extract of Teucrium polium in a rat model of C6-induced glioblastoma.Metabolic brain disease · 2026Article
- The role of the Ki-67 labelling index as an independent prognostic factor in indonesian glioma patients.Histology and histopathology · 2025Article
- Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.Cancers · 2024Review
- Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI.European radiology · 2024Article
- Article
- Prognostic utility and characteristics of MIB-1 labeling index as a proliferative activity marker in childhood low-grade glioma: a retrospective observational study.Journal of cancer research and clinical oncology · 2024Observational
- Complete radiographic response after proton radiation therapy in the re-irradiation of a diffuse high-grade glioma: A case report.SAGE open medical case reports · 2024Article
- An initial study on the predictive value using multiple MRI characteristics for Ki-67 labeling index in glioma.Journal of translational medicine · 2023Article
- Dichotomy in Growth and Invasion from Low- to High-Grade Glioma Cellular Variants.Cellular and molecular neurobiology · 2022Article
- Prognostic Factors of Low-Grade Gliomas in Adults.Current oncology (Toronto, Ont.) · 2022Article
- Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading.Frontiers in oncology · 2022Article
- Glioma grading, molecular feature classification, and microstructural characterization using MR diffusional variance decomposition (DIVIDE) imaging.European radiology · 2021Article
- Monoexponential, biexponential and stretched exponential models of diffusion weighted magnetic resonance imaging in glioma in relation to histopathologic grade and Ki-67 labeling index using high B values.American journal of translational research · 2021Article
- Association between Ki-67 Labeling index and Histopathological Grading of Glioma in Indonesian Population.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.Nature communications · 2018Article
- Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma.Journal of nanobiotechnology · 2018Article
- Machine Learning Models for Multiparametric Glioma Grading With Quantitative Result Interpretations.Frontiers in neuroscience · 2018Article
- Article
- Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.Metabolites · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histopathological malignancy grading of human gliomas is limited by subjective interpretation of the morphological criteria. Assessment of mitotic activity is a cornerstone of grading these tumours, but mitotic figures can be hard to identify in haematoxylin-eosin stained sections. Thus, determining proliferative activity by means of Ki-67/MIB-1 immunostaining has become a useful supplement. However, this method has drawbacks, so continuous testing and evaluation are required for optimization and standardization. The aim of this study was to analyse and evaluate the Ki-67/MIB-1 proliferative indices (PIs) in a series of gliomas. We found that Ki-67/MIB-1 PIs correlated well with histological malignancy grade in all glioma subtypes, but a considerable overlap of PIs was observed between the malignancy groups. Consequently, Ki-67/MIB-1 immunostaining alone is not sufficient to adequately determine the malignancy grade. Therefore, future work is necessary to clarify the role of this immunostaining in the histopathological diagnosis of human gliomas.
Indexed as
Identifiers
25674263PMC4313958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.